Palifermin (marketed as Kepivance)

FDA approves Palifermin, a modified version of a naturally occurring human protein called keratinocyte growth factor (KGF) that is manufactured in a laboratory. Palifermin is used to reduce the chances of developing severe mucositis (injury to the cells lining the mouth) and to shorten the time with severe mucositis in patients with cancer who receive high doses of chemotherapy and radiation therapy followed by stem cell rescue.


Page Last Updated: 07/16/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.